摘要
目的:探讨培美曲塞二钠联合卡铂治疗非小细胞型肺癌的临床疗效。方法:回顾性分析80例非小细胞型肺癌患者临床资料,依据治疗方式不同分为对照组30例和观察组(培美曲塞二钠联合卡铂治疗组)50例。结果:观察组临床治疗总缓解率高于对照组,不良反应发生率低于对照组,P<0.05,差异有统计学意义。结论:美曲塞二钠联合卡铂治疗非小细胞型肺癌临床疗效明显,不良反应少。
Objective：To approach clinical curative effect.Methods：To analyze clinical data of 80 cases Non small cell lung cancer,which were to be divided into control group 30 cases and detection group（ALIMTA combined with carboplatin curing group）50 cases.Results：The total remission rate of detection group were higher than control group,incidence of adverse reactions was lower than control group,P〈0.05,the difference were statistical significance.Conclusion：The clinical curative effect of curing Non small cell lung cancer by ALIMTA combined with carboplatin,the adverse reaction was little.
出处
《中国医药导刊》
2012年第6期1054-1054,1056,共2页
Chinese Journal of Medicinal Guide
关键词
培美曲塞二钠
卡铂
非小细胞型肺癌
ALIMTA
Carboplatin
Lung cancer
Non small cell lung cancer
